Headache

1. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17(11):954–76.

2. Thomson AN, White GE, West R. The prevalence of bad headaches including migraine in a multiethnic community. N Z Med J 1993;106(967):477–80.

3. International Headache Society. International Classification of Headache Disorders, 3rd edition. 2018. https://ichd-3.org

4. Charles A. The evolution of a migraine attack - a review of recent evidence. Headache 2013;53(2):413–19.

5. Ashina M, Terwindt GM, Al-Karagholi MA, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 2021;397(10283):1496–504.

6. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337–45.

7. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50(6):921–36.

8. Wakerley BR. Medication-overuse headache. Pract Neurol 2019;19(5):399–403.

9. Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 2019;19(12):1307–17.